GNPX - Genprex, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

Genprex, Inc.

Health Discovery Building
1601 Trinity Street Building B, Dell Medical Center Suite 3.322
Austin, TX 78712
United States

Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Mr. John Rodney VarnerCo-Founder, CEO, Sec. & Chairman530.42kN/A1957
Dr. Julien L. Pham M.P.H., M.D., MPHPres & COO453.46kN/A1977
Mr. Ryan M. ConferChief Financial Officer358.23kN/A1982
Dr. Jack A. Roth FACS, M.D.Chairman of Scientific & Medical Advisory BoardN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Genprex, Inc. operates as a clinical stage gene therapy company. It is involved in developing various approaches to treating cancer, based upon a proprietary technology platform, including Oncoprex immunogene therapy for non-small cell lung cancer. Oncoprex that has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells and re-establishes pathways for apoptosis, or programmed cell death in cancer cells; and modulates the immune response against cancer cells, as well as blocks mechanisms that create drug resistance. The company was founded in 2009 and is headquartered in Austin, Texas.

Corporate Governance

Genprex, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.